Timm H. Jessen

SCIENAMICS GmbH offers services for life science companies in the area of scientific marketing, business development and strategic consulting. It offers services for public Sector, academia, investors, pharma and biotech companies. The company was founded by Timm H. Jessen on July 1, 2004 and is headquartered in Schleswig, Germany.

Topas Therapeutics GmbH engages in pharmaceutical preparations. The company is headquartered in Hamburg, Germany.

2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark.

DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany.

Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany.

Hmr is a French company that specializes in the restoration of historic monuments. The private company is based in Tossiat, France. The company offers services such as size stone masonry and hemp lime plaster.

bionamics GmbH was an asset management. It used to acquire or license assets in the pre-clinical phase, redirect some as assets for new and appropriate customers or develops these into the clinics, and commercializes the projects into the pharma and biotech industry. The firm offers represent a unique project based investment opportunity. It identifies and evaluates projects from academia, biotech and pharmaceutical companies. The company was headquartered in Kiel, Germany.